Orion S.A.OECEarnings & Financial Report
Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.
OEC Q4 2025 Key Financial Metrics
Revenue
$411.7M
Gross Profit
$77.7M
Operating Profit
$17.9M
Net Profit
$-21.1M
Gross Margin
18.9%
Operating Margin
4.3%
Net Margin
-5.1%
YoY Growth
-5.2%
EPS
$-0.36
Financial Flow
Orion S.A. Q4 2025 Financial Summary
Orion S.A. reported revenue of $411.7M for Q4 2025, with a net profit of $-21.1M (-5.1% margin). Cost of goods sold was $334.0M, operating expenses totaled $59.8M.
Key Financial Metrics
| Total Revenue | $411.7M |
|---|---|
| Net Profit | $-21.1M |
| Gross Margin | 18.9% |
| Operating Margin | 4.3% |
| Report Period | Q4 2025 |
Orion S.A. Annual Revenue by Year
Orion S.A. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.8B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.8B |
| 2024 | $1.9B |
| 2023 | $1.9B |
| 2022 | $2.0B |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $502.9M | $477.0M | $463.4M | $434.2M | $477.7M | $466.4M | $450.9M | $411.7M |
| YoY Growth | 0.4% | 4.0% | -0.6% | -7.3% | -5.0% | -2.2% | -2.7% | -5.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.87B | $1.91B | $2.00B | $1.86B | $1.97B | $2.02B | $1.96B | $1.91B |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $492.2M | $503.9M | $476.3M | $474.9M | $466.1M | $466.5M | $401.8M | $384.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $32.4M | $29.3M | $-30.9M | $94.5M | $400000 | $53.7M | $68.8M | $92.9M |
More Companies
AZN
ASTRAZENECA PLC
Revenue
$14.5B
Net Profit
$2.4B
NVS
NOVARTIS AG
NVO
NOVO NORDISK A S
SNY
Sanofi
GSK
GSK plc
TAK
TAKEDA PHARMACEUTICAL CO LTD
ARGX
ARGENX SE
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Revenue
$1.1B
Net Profit
$186.4M
ALC
ALCON INC
Revenue
$2.6B
Net Profit
$176.0M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Revenue
$4.7B
Net Profit
$481.0M